From: Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up
Feature | Visit 1 | Visit 2 |
---|---|---|
Stage I | 23 (57.5%) | 13 (-10 with CR) |
Stage II | 9 (22.5%) | 8 (-1 with CR) |
Stage III | 8 (20%) | 8 (no CR) |
FEV1 (% predicted) | 92.6 ± 3.2 | 93.8 ± 3.1 |
FVC (% predicted) | 97.9 ± 3.0 | 99.7 ± 2.9 |
FEV1/FVC (%) | 0.81 ± 0.02 | 0.80 ± 0.02 |
DLCOc (% predicted) | 87.3 ± 3.4 | 87.7 ± 3.7 |
LS present and past | 20 (50%) | - |
LS present | 15 (37.5%) | 0 |
SACE > 68 IU/L | 11 (27.5%) | 5 (12.5%) |
S-Ca2+ > 2.62 mmol/L | 1 (2.5%) | 2 (5%) |
U-Ca2+ > 7.5 mmol/24 h | 3 (7.5%) | 5 (12.5%) |
CRP > 5 mg/L | 15 (37.5%) | 5 (12.5%) |
On treatment | 0 | 8 (20%) |
T from first symptoms to V1 (weeks, median: 25-75 percentile) | 10 [4-60] | - |